Given the arrival of AR-targeting agents to the breast cancer clinical arena, the heterogeneous nature of this disease and the dichotomous actions of AR in different breast cancer contexts, the question of whether AR-Vs are expressed in breast malignancies is critically important. Here, AR is linked to breast carcinoma.